KRAS and colorectal carcinoma: We demonstrated that the occurrence frequency of the KRAS/BRAF double-mutant CRC was higher than that reported previously, suggesting that using a larger sample size and improved technologies that cover the sequencing information of WES and CDS datasets of cancer-related genes will be efficient in identifying the rare double mutations at a higher rate.